Silence Therapeutics (SLN)
(Delayed Data from NSDQ)
$5.61 USD
-0.34 (-5.71%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $5.56 -0.05 (-0.89%) 5:24 PM ET
4-Sell of 5 4
C Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SLN 5.61 -0.34(-5.71%)
Will SLN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SLN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLN
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
SLN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
Other News for SLN
Silence Therapeutics Passes Key Resolutions at AGM
SLN: HC Wainwright & Co. Reiterates Buy Rating on Silence Therapeutics | SLN Stock News
SLN: Chardan Capital Maintains Buy Rating and $35 Price Target for Silence Therapeutics | SLN ...
Buy Rating on Silence Therapeutics: Promising Developments in Divesiran and Zerlasiran Programs
Promising Phase 1 Data and Strong Mechanistic Rationale Justify Buy Rating for Silence Therapeutics’ Divesiran in Polycythemia Vera